Ziagen (Abacavir Sulfate)
Brand Names: Ziagen
Methodology & AI Transparency ⓘ
Ziagen (Abacavir Sulfate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Abacavir Sulfate (cross-referenced at /meds/abacavir-sulfate) and registered by ViiV Healthcare Company, Ziagen operates as a prescription brand-name human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor therapy (RxNorm 242679-B49702222; NDC 49702-222).
- 2 Real-world patient consensus: Commercial Ziagen monograph (20 mg/mL Solution) cross-indexed with generic Abacavir Sulfate for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $15.52 on Cost Plus Drugs to $41.13 walk-in retail (NADAC $0.6247/unit).
- 4 Top reported side effects / signs: Most commonly reported Ziagen (Abacavir Sulfate) tolerability events: nausea (9.7%), headache (11.9%), fatigue (7.4%).
Ask our AI Specialists anything about Ziagen (Abacavir Sulfate)
Ziagen (Abacavir Sulfate) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Abacavir Sulfate (cross-referenced at /meds/abacavir-sulfate) and registered by ViiV Healthcare Company, Ziagen operates as a prescription brand-name human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor therapy (RxNorm 242679-B49702222; NDC 49702-222). Under 2024-05-08 FDA labeling for 20 mg/mL Solution; 300mg Tablet, Abacavir oral solution, in combination with other antiretroviral agents, is indicated for the treatment of human.
Bioactive Abacavir Sulfate within Ziagen governs human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor target modulation with class-characteristic hepatorenal disposition. Commercialized across 20 mg/mL Solution; 300mg Tablet (registered by ViiV Healthcare Company, SPL 2024-05-08), Ziagen combines branded dosage-form consistency (NDC 49702-222) with transparent cash-pay comparisons spanning $15.52 to $41.13.
Systemic exposure to Ziagen (Abacavir Sulfate) reflects Oral fraction absorbed ranges from 54% to 66% (Ziagen (Abacavir Sulfate) 20) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of ziagen (abacavir sulfate), sustaining receptor engagement across a Mean elimination half-life of 10 to 16 hours across adult Ziagen (Abacavir Sulfate) dosing half-life window (oral tmax achieved within 2 to 3 hours following ziagen (abacavir sulfate) ingestion response profile).
Dosing protocols (20 mg/mL Solution or 300mg Tablet) balance efficacy (90.00% patient satisfaction across 21 logs) against headache (11.9% of reports), nausea (9.7% of reports), fatigue (7.4% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to ziagen (abacavir sulfate); clinical scenarios where human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor exposure from ziagen (abacavir sulfate) poses unacceptable risk.
Verify medication reconciliation lists so Ziagen (Abacavir Sulfate) is not inadvertently duplicated with another human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Ziagen (Abacavir Sulfate) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Ziagen (Abacavir Sulfate)
- Clinical scenarios where human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor exposure from Ziagen (Abacavir Sulfate) poses unacceptable risk
Logged Side-Effect Incidence (21 Reports)
Ziagen (Abacavir Sulfate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ziagen (Abacavir Sulfate))
Human clinical trial evidence for Ziagen (Abacavir Sulfate) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Ziagen (Abacavir Sulfate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6247/unit (~$18.74/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $15.52 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $41.13 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $17.85 / mo | View logs ↓ |
Ziagen (Abacavir Sulfate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ziagen (Abacavir Sulfate) RxNorm Concept ID | 242679-B49702222 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6247 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $41.13 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.52 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ziagen (Abacavir Sulfate) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Ziagen (Abacavir Sulfate) integrating DailyMed SPL (2024-05-08), CMS NADAC ($0.6247/unit), and 21 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ziagen (Abacavir Sulfate) community threads and patient logs by age, biological sex, dosage, and treatment duration.